Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Oct 20 · below the Ichimoku cloud · RSI 41 · MACD below its signal
| 12.90 | 52-week high | +81.56% |
| 8.90 | Previous month high | +25.26% |
| 7.70 | Previous week high | +8.37% |
| 7.57 | R3 (classic) | +6.50% |
| 7.35 | R2 (classic) | +3.50% |
| 7.28 | Previous month low | +2.46% |
| 7.14 | Previous day high | +0.49% |
| 7.11 | R1 (classic) | +0.02% |
| 7.11 | Price now | |
| 6.89 | Pivot | −2.98% |
| 6.87 | Previous week low | −3.31% |
| 6.68 | Previous day low | −5.98% |
| 6.65 | S1 (classic) | −6.45% |
| 6.43 | S2 (classic) | −9.45% |
| 6.19 | S3 (classic) | −12.93% |
| 4.89 | 52-week low | −31.18% |
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $198.0K | 0.00% | 359.67K | −44% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a RMTI trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 30, 2026 | Strobeck MarkChief Executive Officer | Sale at price 8.42 per share. | 1K | $8.42K |
| Jun 30, 2026 | Cooper John GDirector | Stock Award(Grant) at price 0.00 per share. | 9.6K | — |
| Jun 30, 2026 | Nissenson Allen RDirector | Stock Award(Grant) at price 0.00 per share. | 9.6K | — |
| Jun 30, 2026 | Strobeck MarkChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 30K | — |
| Jun 30, 2026 | Timmins Megan CardenOfficer | Stock Award(Grant) at price 0.00 per share. | 15K | — |
| Jun 30, 2026 | Radie Robert SamuelDirector | Stock Award(Grant) at price 0.00 per share. | 9.6K | — |
| Jun 30, 2026 | Lau JoanDirector | Stock Award(Grant) at price 0.00 per share. | 9.6K | — |
| Jun 30, 2026 | Neri JesseChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 15K | — |
| Jun 30, 2026 | Chole TimothyOfficer | Stock Award(Grant) at price 0.00 per share. | 15K | — |
| Jun 30, 2026 | Hunter Heather R.Chief Operating Officer | Stock Award(Grant) at price 0.00 per share. | 15K | — |
| Jun 30, 2026 | Dawson Joseph H.Director | Stock Award(Grant) at price 0.00 per share. | 9.6K | — |
| Jan 1, 2026 | Neri JesseChief Financial Officer | Sale at price 0.84 per share. | 886 | $740 |
| Jan 1, 2026 | Hunter Heather R.Chief Operating Officer | Sale at price 0.84 per share. | 2.9K | $2.40K |
| Nov 17, 2025 | Cooper John GDirector | Sale at price 0.87 per share. | 5.1K | $4.42K |
| Nov 16, 2025 | Dawson Joseph H.Director | — | 25K | — |
| Sep 30, 2025 | Strobeck MarkChief Executive Officer | Sale at price 1.19 per share. | 6.9K | $8.24K |
| Sep 30, 2025 | Neri JesseChief Financial Officer | Sale at price 1.19 per share. | 886 | $1.05K |
| Sep 30, 2025 | Chole TimothyOfficer | Sale at price 1.19 per share. | 2.9K | $3.41K |
| Sep 30, 2025 | Hunter Heather R.Chief Operating Officer | Sale at price 1.19 per share. | 2.9K | $3.41K |
| Jun 30, 2025 | Strobeck MarkChief Executive Officer | Sale at price 0.82 per share. | 6.9K | $5.68K |
TimeframesThe daily, weekly and monthly trends are down; the hourly is steadying, a bounce inside them.
bouncing over the 21 EMA
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 28.9 | -15.9 | -1.1 | -1.1 | -15.9 | -25.7 | 30.7 | 15.6 | 2.8 | -16.8 | −14.4% | ||
| 2025 | 0.0 | -18.1 | -32.3 | -4.4 | -9.3 | -13.3 | 9.4 | 83.9 | -29.8 | -7.5 | -9.9 | -17.0 | −59.3% |
| 2024 | -30.2 | 6.8 | 17.7 | -12.0 | 20.5 | 0.0 | 4.0 | 56.3 | 38.8 | -8.1 | -37.3 | -10.9 | +7.9% |
| 2023 | 47.5 | 10.1 | 10.4 | 52.5 | 20.3 | 64.5 | -34.6 | -34.7 | -10.7 | -14.4 | 0.6 | 5.6 | +87.1% |
| 2022 | 0.0 | -17.1 | 38.2 | -29.8 | -54.8 | -21.3 | 10.1 | 27.5 | -27.1 | -25.8 | 11.2 | -7.3 | −77.6% |
| 2021 | 18.8 | 12.5 | -14.1 | -17.2 | -9.4 | 4.6 | -19.8 | -9.6 | -9.1 | -10.0 | -20.4 | -4.7 | −59.4% |
| 2020 | 7.0 | 7.7 | -27.0 | 13.7 | -8.2 | -8.9 | -11.8 | -23.8 | -18.3 | -20.6 | 23.5 | -3.8 | −58.6% |
| 2019 | 38.1 | 49.0 | 22.4 | -15.5 | -4.4 | -34.6 | -11.6 | -3.8 | 7.8 | -19.9 | 3.2 | 7.0 | +8.0% |
| 2018 | -4.1 | 4.5 | -10.6 | 1.5 | 1.7 | -8.4 | -17.6 | 20.9 | -14.1 | -3.3 | -18.9 | -31.7 | −61.2% |
| 2017 | -11.3 | 2.2 | 5.4 | 37.4 | -16.7 | 10.8 | -10.1 | -11.4 | 35.4 | -29.2 | 1.2 | -5.1 | −11.1% |
| 2016 | -38.9 | 53.4 | -21.8 | 23.2 | 3.7 | -21.1 | 6.3 | -9.8 | -7.7 | -13.3 | 11.9 | 0.8 | −36.0% |
| 2015 | 5.0 | -7.3 | 9.3 | -11.2 | 14.0 | 45.6 | -14.4 | -13.3 | -35.6 | 50.2 | 4.7 | -15.6 | −0.4% |
| 2014 | -1.7 | 23.7 | -0.2 | -19.7 | 10.8 | 6.5 | -15.8 | -5.5 | -4.2 | -4.6 | 2.6 | 14.9 | −1.5% |
| 2013 | -24.0 | -27.9 | -10.2 | 7.1 | -2.8 | -12.4 | 39.9 | 9.5 | 106.1 | 1.0 | 27.1 | -28.6 | +29.7% |
| 2012 | 27.9 | -12.4 | -0.3 | -2.2 | -8.0 | 9.4 | -3.1 | -11.5 | 2.4 | -12.1 | 1.4 | 10.6 | −5.0% |
| 2011 | 18.5 | -2.6 | -1.5 | 14.4 | 46.1 | -14.4 | -16.6 | -15.8 | -9.5 | 3.3 | -10.4 | 12.2 | +7.2% |
| 2010 | -8.5 | -15.3 | -3.0 | 0.5 | -4.8 | -3.3 | 1.1 | 8.7 | 20.4 | 20.6 | -8.8 | 1.4 | +2.7% |
| 2009 | -13.8 | 3.6 | 13.6 | 16.9 | 22.1 | 24.4 | 18.9 | -10.8 | -2.9 | -13.2 | -8.0 | 23.8 | +83.5% |
| 2008 | -8.6 | -2.1 | -4.7 | -9.6 | 10.3 | 14.9 | -14.6 | -16.7 | -17.0 | -36.7 | 42.0 | 12.6 | −41.6% |
| 2007 | -6.9 | 14.5 | -10.5 | -4.4 | -2.5 | -13.2 | -3.5 | -2.3 | 9.8 | 28.1 | 3.3 | -4.8 | +0.7% |
Rockwell Medical, Inc., together with its subsidiaries, engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. It offers citrapure citric acid concentrate, dri-sate dry acid concentrate, renalpure liquid acid concentrate, dri-sate acid concentrate mixer, renalpure acid concentrate, renalpure bicarbonate concentrate, sterilyte bicarbonate concentrate, bicarbonate cartridges, and dry acid concentrate mixer, as well as ancillary products, including 5% acetic acid, cleaner, citric acid descaler, water softener salt pellets, and other supplies used by hemodialysis providers. The company's hemodialysis concentrate products are used to sustain patient's life by removing toxins and balancing electrolytes in a dialysis patient's bloodstream. In addition, it offers dialysis concentrates, dialysis kits, and other ancillary products used in the dialysis process. The company was formerly known as Rockwell Medical Technologies, Inc. and changed its name to Rockwell Medical, Inc. in June 2012. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.
Buy / hold / sell counts